Comparative Pharmacology
Head-to-head clinical analysis: AURLUMYN versus CLOFARABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURLUMYN versus CLOFARABINE.
AURLUMYN vs CLOFARABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateClofarabine + Digoxin
"Clofarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateClofarabine + Digitoxin
"Clofarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateClofarabine + Deslanoside
"Clofarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateClofarabine + Acetyldigitoxin
"Clofarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent